Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: A systemic review and meta-analysis

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1125-1132

  Liu, Yu ^a   Yin, Tie Jun ^a   Zhou, Rong ^a   Zhou, Si ^a   Fan, Liang ^a   Zhang, Rong Ge ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemotherapy; Meta analysis; Non small cell lung cancer; Pemetrexed; Predictive biomarkers; Thymidylate synthase

Indexed keywords

MESSENGER RNA; PEMETREXED; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; GLUTAMIC ACID DERIVATIVE; GUANINE; TUMOR PROTEIN;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; GENE EXPRESSION REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TS GENE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; ENZYMOLOGY; LUNG; LUNG NEOPLASMS; METABOLISM; PROGNOSIS; SURVIVAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE;

EID: 84887135521     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2299-2     Document Type: Review

References (39)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11-30. doi: 10.3322/caac.21166
2. Wakelee H, Belani CP (2005) Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10(Suppl 3):1-10. doi: 10.1634/theoncologist.10-90003-1 (Pubitemid 43152725)
3. Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC (2012) Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 13(3):292-299. doi: 10.1016/s1470-2045(11)70339-4
4. Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M (2012) Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol 7(3):567-573. doi: 10.1097/JTO. 0b013e31823d4f9d
5. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR (2006) A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clinical Cancer Res Off J Am Assoc Cancer Res 12(3 Pt 1):832-838. doi: 10.1158/1078-0432.CCR-05-0295 (Pubitemid 43259865)
6. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22(3):529-536. doi: 10.1200/JCO.2004.05.064 (Pubitemid 41079782)
7. Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28(9):1534-1539. doi: 10.1200/JCO.2009.25.9275
8. Lustgarten DES, Deshpande C, Aggarwal C, Wang L-C, Saloura V, Vachani A, Wang L-P, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM (2013) Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 8(4):469-477. doi: 10.1097/JTO.0b013e318283da3e
9. Tanaka F, Wada H, Fukui Y, Fukushima M (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 22(8):1791-1797. doi: 10.1093/annonc/mdq730
10. Scagliotti GV, Ceppi P, Capelletto E, Novello S (2009) Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 10(Suppl 1):S35-S40. doi: 10.3816/CLC.2009.s.006
11. Rossi A, Galetta D, Gridelli C (2009) Biological prognostic and predictive factors in lung cancer. Oncology 77(Suppl 1):90-96. doi: 10.1159/000258500
12. Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G (2008) Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 112(12):2765-2773. doi: 10.1002/cncr.23491 (Pubitemid 351969222)
13. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K (2011) Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 104(10):1594-1601
14. Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K (2010) The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 69(3):323-329
15. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA (2008) Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112-1118
16. Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A (2011) Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol 6(5):927-933. doi: 10.1097/JTO.0b013e3182156109
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi: 10.1186/1745-6215-8-16 (Pubitemid 47161711)
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560. doi: 10.1136/bmj.327. 7414.557 (Pubitemid 37088507)
19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634 (Pubitemid 27387172)
20. Wynes MW, Konopa K, Singh S, Reyna-Asuncion B, Ranger-Moore J, Sternau A, Christoph DC, Dziadziuszko R, Jassem J, Hirsch FR (2012) Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol 7(6):982-992. doi: 10.1097/JTO.0b013e31824fe95a
21. Hou J, Lambers M, den Hamer B, den Bakker MA, Hoogsteden HC, Grosveld F, Hegmans J, Aerts J, Philipsen S (2012) Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol 7(1):105-114. doi: 10.1097/JTO.0b013e3182352a45
22. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78(1):92-99. doi: 10.1016/j.lungcan.2012.07.009
23. Smit EF, Socinski MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohannesian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N (2012) Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol 23(7):1723-1729
24. Smit EF, Burgers SA, Biesma B, Smit HJM, Eppinga P, Dingemans A-MC, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJM (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27(12):2038-2045. doi: 10.1200/JCO.2008.19.1650
25. Hu Q, Li X, Su C, Chen X, Gao G, Zhang J, Zhao Y, Li J, Zhou C (2012) Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med 4(6):1010-1016
26. Li WJ, Jiang H, Fang XJ, Ye HL, Liu MH, Liu YW, Chen Q, Zhang L, Zhang JY, Yuan CL, Zhang QY (2013) Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett 5(4):1165-1170
27. Wang X, Wang Y, Wang Y, Cheng J, Wang Y, Ha M (2013) Association of thymidylate synthase gene 3′-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci 20(1)
28. Shimizu T, Nakanishi Y, Nakagawa Y, Tsujino I, Takahashi N, Nemoto N, Hashimoto S (2012) Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res 32(10):4589-4596
29. Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR (2013) Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 8(1):19-30
30. Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y, Masuda N (2012) Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy 58(4):313-320
31. Sun J-M, Han J, Ahn JS, Park K, Ahn M-J (2011) Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6(8):1392-1399. doi: 10.1097/JTO.0b013e3182208ea8
32. Chen C-Y, Chang Y-L, Shih J-Y, Lin J-W, Chen K-Y, Yang C-H, Yu C-J, Yang P-C (2011) Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 74(1):132-138. doi: 10.1016/j.lungcan.2011.01.024
33. Lee SH, Noh KB, Lee JS, Lee EJ, Min KH, Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, Shin C, Shim JJ, Kim CH, Kang KH, In KH (2013) Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81(1):102-108. doi: 10.1016/j.lungcan.2013.03.002
34. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957. doi: 10.1056/NEJMoa0810699
35. Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS ONE 6(10):e25164. doi: 10.1371/journal.pone.0025164
36. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(29):4731-4737. doi: 10.1200/JCO.2006.06.1101 (Pubitemid 46646245)
37. Moreira LR, Schenka AA, Latuff Filho P, Nascimento H, Passos Lima CS, Silva Trevisan MA, Vassallo J (2009) Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma. Int J Surg Pathol 17(3):181-186. doi: 10.1177/ 1066896908330480
38. Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol J-L, Douillard J-Y, Kudoh S, Pignon J-P, Quinaux E, Buyse M (2013) Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open 3(3). doi: 10.1136/bmjopen-2012-001802
39. Biesecker LG, Spinner NB (2013) A genomic view of mosaicism and human disease. Nat Rev Genet 14(5):307-320. doi: 10.1038/nrg3424